Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase IIa Trial for Garutadustat (ISM5411) (IMAGE)

InSilico Medicine

Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase IIa Trial for Garutadustat (ISM5411)

Caption

Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570), which has recently been granted the generic name of Garutadustat by the United States Adopted Names (USAN) Council. Garutadustat (originally ISM5411) is a novel, gut-restricted PHD inhibitor developed with Pharma.AI, Insilico’s generative platform, for the treatment of Inflammatory Bowel Disease (IBD). 

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.